Last reviewed · How we verify
Sucraid (SACROSIDASE)
At a glance
| Generic name | SACROSIDASE |
|---|---|
| Sponsor | Qol Medcl |
| Drug class | Sucrose-specific Enzyme [EPC] |
| Modality | Enzyme |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 1998 |
Approved indications
- Sucrase-isomaltase deficiency
Common side effects
- abdominal pain
- vomiting
- nausea
- diarrhea
- constipation
- insomnia
- headache
- nervousness
- dehydration
- wheezing
Key clinical trials
- 7-Day Trial of Sucraid for Alleviating CSID Symptoms in Subjects With Low, Moderate, and Normal Sucrase Levels (PHASE4)
- Effects of Sacrosidase and Placebo in Subjects With Fructan Intolerance (PHASE2)
- Adult Pilot Study for Reference Ranges and Optimal Cut-offs for the Sucrose Challenge Test and Sucrose Breath Test
- A Trial to Evaluate the Frequency of Genetic Sucrase-Isomaltase Deficiency Genotypes, and the Efficacy and Safety of Sucraid® (Sacrosidase) Oral Solution in Subjects With Chronic Diarrhea and Sucrase Deficiency (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |